Urinary Peptides Significantly Associate with COVID‐19 Severity: Pilot Proof‐of‐Principle Data and Design of a Multicentric Diagnostic Study
Open Access
- 10 September 2020
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 20 (24) , e2000202
Abstract
SARS‐CoV‐2 infection results in a mild‐to‐moderate disease course in most patients, allowing outpatient self‐care and quarantine. However, in ≈10% of cases a two‐ or three‐phasic critical disease course with starting from day 7 to 10 is observed. To facilitate and plan outpatient care, biomarkers prognosing such worsening at an early stage appear of outmost importance. In this accelerated article, the identification of urinary peptides significantly associated with SARS‐CoV‐2 infection, and the development of a multi‐marker urinary peptide based test, COVID20, that may enable prognosis of critical and fatal outcomes in COVID‐19 patients is reported. COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity. Based on the performance in this pilot study, testing in a prospective study on 1000 patients has been initiated.Keywords
Funding Information
- Bundesministerium für Gesundheit
This publication has 33 references indexed in Scilit:
- Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficitsBrain, 2010
- Addressing the Challenge of Defining Valid Proteomic Biomarkers and ClassifiersBMC Bioinformatics, 2010
- Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney DiseaseMolecular & Cellular Proteomics, 2010
- Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individualsJournal Of Hypertension, 2010
- Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney DiseaseJournal of Proteome Research, 2008
- Capillary electrophoresis–mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developmentsMass Spectrometry Reviews, 2008
- CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnosticsProteomics – Clinical Applications, 2008
- Biomarker discovery by CE‐MS enables sequence analysis via MS/MS with platform‐independent separationElectrophoresis, 2006
- Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface‐enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometryRapid Communications in Mass Spectrometry, 2003
- The control of the false discovery rate in multiple testing under dependencyThe Annals of Statistics, 2001